Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M

CORCEPT THERAPEUTICS INC

2025-Q3 EPS reported $0.62 revenue$559,282,000

Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.
Modified 2025 revenue guidance to $800-850M, citing capacity constraints at prior specialty pharmacy.
Cash and investments $524.2M; repurchased $50.6M in stock during Q3.
NDA for relacorilant in hypercortisolism PDUFA Dec 30, 2025; NDA for ovarian cancer PDUFA July 11, 2026.
New oncology trials starting: Phase 2 in earlier-stage ovarian, endometrial, cervical, pancreatic cancers; Phase 1b for nenocorilant with immunotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.